Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing
Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient o...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
October 2012
|
| In: |
Transplantation reviews
Year: 2012, Jahrgang: 26, Heft: 4, Pages: 233-240 |
| ISSN: | 1557-9816 |
| DOI: | 10.1016/j.trre.2012.02.001 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.trre.2012.02.001 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0955470X12000158 
|
| Verfasserangaben: | Matthew Cooper, Maurizio Salvadori, Klemens Budde, Frederic Oppenheimer, Hans Sollinger, Martin Zeier |
| Zusammenfassung: | Mycophenolate mofetil (MMF), a mycophenolic acid (MPA) formulation, has improved both short- and long-term outcomes following renal transplantation, but is often associated with gastrointestinal (GI) complications that can lead to dose reduction or discontinuation, potentially jeopardizing patient outcomes. Enteric-coated mycophenolate sodium (EC-MPS) delivers equivalent MPA exposure to MMF and offers the potential to reduce GI burden (while maintaining patient safety). Here we review the efficacy of EC-MPS compared with MMF in renal transplant patients in terms of biopsy-proven acute rejection and graft loss, and examine the use of EC-MPS in newer regimens such as intensified dosing and calcineurin inhibitor minimization. |
|---|---|
| Beschreibung: | Available online 2 August 2012 Gesehen am 09.10.2018 |
| Beschreibung: | Online Resource |
| ISSN: | 1557-9816 |
| DOI: | 10.1016/j.trre.2012.02.001 |